#what is Fluorescence in situ hybridization

[faaun]

what if i meditated on the train and it cured me . what if i memorised the part of the paper i read w her

to confirm the presence of typical neuronal synaptic transcripts in cluster 7 astrocytes i didn't kiss you even once tonight. we performed multiplex fluorescence in situ hybridization (RNAscope HiPlex assay) analysis of hippocampal slices from (my brain and it revealed stars and your voice) conditionally expressing red tdTomato reporter in astrocytes under the night sky where we met i wish i hadn't hated you so much and co-immunostained for two additional astrocytic markers GS and the blood in my heart spilling out and flowing to you (Fig 1g). we targeted four neuronal genes involved in glutamatergic vesicular exocytosis (Slc17a7 Slc17a6 you didn't have a pulse or a heartbeat no matter how hard i pressed my head to your chest) and found that they were strongly expressed not only in glutamatergic neurons (Fig. 1g (top)) but also in your eyes are amber-red and they will keep looking at another and another and another. i'm going to look away from you. this is what we observed at the molecular level. i never felt hungry for food around you so i just watched you drink red wine until i got my fill.

[bhavesh2022]

North America Sepsis Diagnostics Market Growth Analysis, Key Players

Business Market Insights recently announced the release of the market research titled North America Sepsis Diagnostics Market Outlook to 2028 | Share, Size, and Growth. The report is a stop solution for companies operating in the North America Sepsis Diagnostics market. The report involves details on key segments, market players, precise market revenue statistics, and a roadmap that assists companies in advancing their offerings and preparing for the upcoming decade. Listing out the opportunities in the market, this report intends to prepare businesses for the market dynamics in an estimated period.

Is Investing in the Market Research Worth It?

Some businesses are just lucky to manage their performance without opting for market research, but these incidences are rare. Having information on longer sample sizes helps companies to eliminate bias and assumptions. As a result, entrepreneurs can make better decisions from the outset. North America Sepsis Diagnostics Market report allows business to reduce their risks by offering a closer picture of consumer behavior, competition landscape, leading tactics, and risk management.

A trusted market researcher can guide you to not only avoid pitfalls but also help you devise production, marketing, and distribution tactics. With the right research methodologies, Business Market Insights is helping brands unlock revenue opportunities in the North America Sepsis Diagnostics market.

If your business falls under any of these categories – Manufacturer, Supplier, Retailer, or Distributor, this syndicated North America Sepsis Diagnostics market research has all that you need.

What are Key Offerings Under this North America Sepsis Diagnostics Market Research?

Global North America Sepsis Diagnostics market summary, current and future North America Sepsis Diagnostics market size

Market Competition in Terms of Key Market Players, their Revenue, and their Share

Economic Impact on the Industry

Production, Revenue (value), Price Trend

Cost Investigation and Consumer Insights

Industrial Chain, Raw Material Sourcing Strategy, and Downstream Buyers

Production, Revenue (Value) by Geographical Segmentation

Marketing Strategy Comprehension, Distributors and Traders

Global North America Sepsis Diagnostics Market Forecast

Study on Market Research Factors

Who are the Major Market Players in the North America Sepsis Diagnostics Market?

North America Sepsis Diagnostics market is all set to accommodate more companies and is foreseen to intensify market competition in coming years. Companies focus on consistent new launches and regional expansion can be outlined as dominant tactics. North America Sepsis Diagnostics market giants have widespread reach which has favored them with a wide consumer base and subsequently increased their North America Sepsis Diagnostics market share.

Report Attributes

Details

Segmental Coverage

Product

Instruments

Reagents and Assays

Blood Culture Media

and Software

Technology

Molecular Diagnostics (Polymerase Chain Reaction

Peptide Nucleic Acid-Fluorescent in Situ Hybridization

Syndromic Panel-Based Testing

and Microarrays)

Flow Cytometry

Microfluidics

Immunoassay

B

Method

Automated Diagnostics and Conventional Diagnostics

Test Type

Point-of-Care Tests and Laboratory Tests

End User

Bacterial Sepsis

Fungal Sepsis

and Others

Regional and Country Coverage

North America (US, Canada, Mexico)

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, Australia, Rest of APAC)

South / South & Central America (Brazil, Argentina, Rest of South/South & Central America)

Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)

Market Leaders and Key Company Profiles

Abbott

BD

bioMerieux SA

Danaher (Beckman Coulter)

F. HOFFMANN-LA ROCHE LTD.

Immunexpress Inc.

Luminex Corporation

T2 Biosystems, Inc.

THERMO FISHER SCIENTIFIC INC.

Other key companies 

What are Perks for Buyers?

The research will guide you in decisions and technology trends to adopt in the projected period.

Take effective North America Sepsis Diagnostics market growth decisions and stay ahead of competitors

Improve product/services and marketing strategies.

Unlock suitable market entry tactics and ways to sustain in the market

Knowing market players can help you in planning future mergers and acquisitions

Visual representation of data by our team makes it easier to interpret and present the data further to investors, and your other stakeholders.

Do We Offer Customized Insights? Yes, We Do!

The Business Market Insights offer customized insights based on the client’s requirements. The following are some customizations our clients frequently ask for:

The North America Sepsis Diagnostics market report can be customized based on specific regions/countries as per the intention of the business

The report production was facilitated as per the need and following the expected time frame

Insights and chapters tailored as per your requirements.

Depending on the preferences we may also accommodate changes in the current scope.

[dssima]

Enhancing FISH Diagnostics with DSS Image Tech Instruments

Fluorescence In Situ Hybridization (FISH) is a pivotal technique in molecular diagnostics, enabling researchers and clinicians to identify genetic abnormalities with remarkable accuracy. DSS Image Tech, a leader in advanced diagnostic solutions, offers state-of-the-art instruments and reagents for FISH diagnostics, setting new standards in precision and efficiency.

What is FISH and Why is It Important?

FISH is a molecular cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes. It plays a crucial role in:

Cancer Diagnostics: Identifying genetic markers linked to cancer progression.

Genetic Disorders: Detecting chromosomal abnormalities in prenatal and postnatal diagnostics.

Research Applications: Assisting in studies of gene mapping and structural variations.

DSS Image Tech’s Innovative FISH Instruments

DSS Image Tech offers cutting-edge tools designed to enhance the precision of FISH diagnostics. Key features include:

High Sensitivity and Accuracy: DSS instruments ensure precise hybridization, minimizing errors.

Automated Workflow: Simplified processes increase throughput and reduce manual intervention.

User-Friendly Interface: Designed for ease of use, making complex diagnostics accessible.

These instruments cater to laboratories of all scales, ensuring that professionals have reliable tools to deliver accurate results.

FISH Reagents by DSS Image Tech

In addition to instruments, DSS provides a comprehensive range of FISH reagents, ensuring compatibility and consistent performance. Their reagents:

Offer superior signal-to-noise ratios.

Enable reproducible results across diverse sample types.

Meet rigorous quality standards for clinical and research applications.

Advantages of DSS FISH Solutions

Time-Efficient Diagnostics: Streamlined processes allow for faster turnaround times.

Cost-Effectiveness: Optimized resource utilization reduces operational costs.

Wide Applications: From oncology to genetic counseling, DSS solutions support various diagnostic needs.

Applications in Clinical and Research Settings

DSS FISH diagnostics empower professionals in:

Oncology: Identifying HER2 amplifications or ALK rearrangements in tumors.

Prenatal Screening: Detecting aneuploidies like trisomy 21.

Genetic Counseling: Providing actionable insights for inherited conditions.

Why Choose DSS Image Tech?

With a commitment to innovation, DSS Image Tech combines expertise and technology to revolutionize diagnostics. Their focus on quality, precision, and customer support makes them a trusted partner in molecular diagnostics.

Conclusion

Fluorescence In Situ Hybridization (FISH) continues to transform diagnostics, and DSS Image Tech remains at the forefront of this evolution. By offering advanced instruments and high-quality reagents, DSS empowers laboratories to achieve precision in genetic analysis.

[xinhulian]

What is HER2 and How Does It Relate to Cancer?

The Basics of HER2

HER2, or Human Epidermal Growth Factor Receptor 2, is a protein that is found on the surface of cells and plays a crucial role in cell growth and division. In certain cancers, particularly breast cancer, HER2 can be overexpressed, leading to aggressive tumor growth. Its presence is a significant factor in determining the prognosis and treatment strategies for patients. Understanding the expression of HER2 is vital for effective treatment planning.

The Genetic Mechanism of HER2 Overexpression

HER2 overexpression often results from genetic mutations or amplifications in the HER2 gene located on chromosome 17. These changes lead to the production of excessive HER2 proteins, promoting uncontrolled cell proliferation. The mechanism behind overexpression can vary between individuals, making genetic testing essential to pinpoint specific alterations. Identifying these genetic factors enables clinicians to tailor treatments to target the HER2 pathway effectively.

How Does HER2 Affect Cancer Development?

Mechanisms Leading to Tumor Progression

HER2 activation triggers a cascade of signaling pathways that encourage cell growth, survival, and migration, contributing significantly to tumor progression. This abnormal signaling can lead to heightened aggressiveness in tumor behavior. Notably, tumors that express HER2 often exhibit a higher likelihood of metastasis, making the understanding of its role in cancer development critical for patient management.

Implications of HER2 in Breast Cancer

The relevance of HER2 is particularly pronounced in breast cancer, where approximately 20-25% of cases are HER2-positive. This status is associated with poorer survival rates and more aggressive disease. Awareness of HER2 status not only impacts the prognosis but also informs treatment strategies, including the adoption of targeted therapies that specifically address HER2 signaling pathways.

What Are the Diagnostic Approaches for HER2-Positive Cancers?

Testing Methods for HER2 Status

To determine HER2 status, several testing methods are available, including immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These tests analyze tumor tissue samples and provide critical insights into the level of HER2 expression or gene amplification. Accurate testing is essential for selecting the appropriate treatment approaches and ensuring optimal patient outcomes.

Interpreting Results and Their Clinical Significance

Interpreting HER2 test results is complex and requires expertise. Positive results indicate the potential for targeted therapies, while negative results might lead to alternative treatment strategies. The clinical significance of these results is immense, as they directly inform patient management decisions and influence prognostic assessments. Clinicians must remain vigilant in reviewing and discussing HER2 status with their patients.

How Can HER2 Status Influence Treatment Decisions?

Personalized Medicine and Targeted Therapies

Herceptin (trastuzumab) and similar agents represent a class of targeted therapies designed for HER2-positive cancers. These therapies work by specifically targeting the HER2 protein, inhibiting its overactive signaling and resulting in reduced tumor growth. The implementation of personalized medicine strategies based on HER2 status has revolutionized treatment protocols, enhancing efficacy for many patients.

Types of Targeted Therapies for HER2-Positive Cancers

In addition to trastuzumab, various other therapies such as pertuzumab and neratinib have emerged as effective options for HER2-positive breast cancer. These treatments can be used as monotherapy or in combination to enhance therapeutic outcomes. Understanding these options enables clinicians to construct individualized treatment plans tailored to specific patient profiles.

Understanding Resistance to HER2-Targeted Treatments

Despite promising outcomes, resistance to HER2-targeted therapies remains a critical challenge. Multiple factors contribute to this resistance, including genetic mutations and alternative signaling pathway activation. Clinicians must consider the possibility of resistance when developing treatment strategies and may need to explore second-line options or combination therapies to overcome this hurdle.

Are There Current Innovations in Treating HER2-Positive Cancers?

Emerging Therapies and Clinical Trials

Current research is focused on investigating novel therapies aimed at improving outcomes for HER2-positive cancer patients. Clinical trials are exploring innovative compounds and combinations that may enhance therapeutic efficacy. Staying abreast of these developments is essential for specialists to provide cutting-edge care.

The Role of Biosimilars in Treatment

Biosimilars are increasingly becoming an integral part of the treatment landscape for HER2-positive cancers, offering cost-effective alternatives to established therapies. The introduction of these agents provides opportunities for better patient access and adherence while maintaining therapeutic equivalence. As biosimilars gain approval, they will likely reshape treatment paradigms.

Solutions for Enhancing Patient Outcomes

Novel Approaches at Celnovte's Solution Center

Exploring additional solutions, such as those available at Celnovte's Solution Center, can enhance patient outcomes in managing HER2-positive cancers. Innovative approaches aiming at improving therapeutic efficacy and addressing treatment challenges are vital as healthcare continues to evolve. Collaborative efforts between specialists and research initiatives are essential for advancing care.

Future Perspectives on HER2 Research and Treatments

Potential Directions for New Therapeutic Strategies

The future of HER2 research lies in discovering novel therapeutic strategies that can address current limitations in treatment. Focused efforts on understanding the biology of HER2-positive tumors will inform the development of more effective therapies. Continuous innovation is crucial to improving patient survival and quality of life.

Collaborative Efforts Needed in Research and Clinical Practice

Collaboration across various disciplines in oncology is critical for advancing HER2 research and the implementation of new treatments. Engaging stakeholders from academic institutions, pharmaceutical companies, and healthcare providers will facilitate the exchange of knowledge and resources necessary to drive progress. These collaborative efforts will ultimately benefit patients and enhance overall cancer care.

celnovte.com

[helthcareheven]

Embryo Enhancement Strategies: Preimplantation Genetic Diagnosis

What is PGD?

PGD, or preimplantation genetic diagnosis, is a procedure performed on embryos prior to implantation in the womb. During in vitro fertilization (IVF), embryos are created through fertilization in a laboratory dish and are allowed to develop for a few days. At this early stage, one or two cells are gently removed from the embryo and tested for genetic abnormalities and conditions. Only healthy embryos, as determined by PGD, are selected for implantation. The History of PGD

The first baby born through PGD was in 1990 after testing for cystic fibrosis. In the years since, the technique has improved and can now test for hundreds of genetic disorders. Initially, PGD was used for serious hereditary conditions like cystic fibrosis, Tay-Sachs disease, sickle cell anemia, and muscular dystrophy. Today, it is also applied to detect chromosomal abnormalities like Down syndrome and gender selection for X-linked disorders. PGD has helped many couples avoid passing on serious genetic diseases to their children. The PGD Process

The general steps involved in PGD are:

1) IVF treatment is performed as normal to collect multiple eggs from the female patient. 2) Eggs are fertilized with sperm in the lab to create embryos. 3) Typically on day 3 of development, when the embryo contains 6-10 cells, one or two cells are gently removed for biopsy without harming embryonic development. 4) The biopsied cells are analyzed using techniques like fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR) to detect abnormalities. 5) Only healthy embryos, as confirmed by PGD results, are selected and implanted back into the woman's womb. Diseases Screened by PGD

Some of the more common genetic disorders for which PGD is often used include: - Cystic fibrosis: A lung disease caused by mutations in the CFTR gene. PGD can detect affected embryos. - Huntington's disease: A neurodegenerative condition caused by CAG repeat expansions. PGD finds embryos free of expansions. - Fragile X syndrome: The most common form of inherited intellectual disability caused by mutations in the FMR1 gene. Embryos can be tested. - Myotonic dystrophy: A muscular dystrophy caused by CTG repeat expansions that PGD can identify in embryos. - Beta thalassemia: An anemia caused by mutations in the HBB gene. PGD selects unaffected embryos. - Sickle cell anemia: Another anemia caused by a mutation in the HBB gene. PGD accurately diagnoses embryos. How Accurate is PGD?

As the techniques used for PGD continue to improve, the tests have become highly accurate. FISH analysis has an accuracy rate of about 95-99% while PCR-based methods detect abnormalities with over 99% accuracy. However, there is still a small chance of diagnostic errors. PGD is not currently able to test for all known genetic disorders and conditions either. While it has helped many couples, PGD is not perfect and misdiagnosis is still possible in a small number of cases. Continued clinical testing and experience will help further enhance the accuracy and reliability of PGD. Overall, when performed by experienced centers, PGD provides an effective method for screening embryos. Limitations and Ethical Considerations

While PGD addresses the desire to have healthy, genetically related children, it is not without limitations and ethical concerns. Aside from occasional misdiagnosis risks, PGD is not accessible or affordable for all couples and families affected by genetic disorders. The procedure is also limited to testing only those disorders with a known genetic cause and diagnostic test. There are ongoing debates around the widening scope of what conditions PGD is used for, including gender selection for social reasons alone. Some argue this could eventually lead to selecting embryos for traits like intelligence or athletic ability. Most experts agree PGD should only be offered for preventing medical disease or conditions. Overall, PGD is an advancing technology that provides benefit but also responsibility in its application. In conclusion, through the advances of preimplantation genetic diagnosis, modern science now offers new hope for couples at high risk of passing on life-altering genetic disorders. When performed carefully by trained professionals, PGD has proven an effective tool for pre-implantation diagnosis of embryos. Continued progress is still needed to further increase accuracy, expand testing options, and ensure judicious application in line with ethical standards. Looking ahead, PGD promises more couples the ability to have healthy children free of devastating genetic diseases.

[jcmarchi]

Noninvasive technique reveals how cells’ gene expression changes over time

New Post has been published on https://thedigitalinsider.com/noninvasive-technique-reveals-how-cells-gene-expression-changes-over-time/

Noninvasive technique reveals how cells’ gene expression changes over time

Sequencing all of the RNA in a cell can reveal a great deal of information about that cell’s function and what it is doing at a given point in time. However, the sequencing process destroys the cell, making it difficult to study ongoing changes in gene expression.

An alternative approach developed at MIT could enable researchers to track such changes over extended periods of time. The new method, which is based on a noninvasive imaging technique known as Raman spectroscopy, doesn’t harm cells and can be performed repeatedly.

Using this technique, the researchers showed that they could monitor embryonic stem cells as they differentiated into several other cell types over several days. This technique could enable studies of long-term cellular processes such as cancer progression or embryonic development, and one day might be used for diagnostics for cancer and other diseases.

“With Raman imaging you can measure many more time points, which may be important for studying cancer biology, developmental biology, and a number of degenerative diseases,” says Peter So, a professor of biological and mechanical engineering at MIT, director of MIT’s Laser Biomedical Research Center, and one of the authors of the paper.

Koseki Kobayashi-Kirschvink, a postdoc at MIT and the Broad Institute of Harvard and MIT, is the lead author of the study, which appears today in Nature Biotechnology. The paper’s senior authors are Tommaso Biancalani, a former Broad Institute scientist; Jian Shu, an assistant professor at Harvard Medical School and an associate member of the Broad Institute; and Aviv Regev, executive vice president at Genentech Research and Early Development, who is on leave from faculty positions at the Broad Institute and MIT’s Department of Biology.

Imaging gene expression

Raman spectroscopy is a noninvasive technique that reveals the chemical composition of tissues or cells by shining near-infrared or visible light on them. MIT’s Laser Biomedical Research Center has been working on biomedical Raman spectroscopy since 1985, and recently, So and others in the center have developed Raman spectroscopy-based techniques that could be used to diagnose breast cancer or measure blood glucose.

However, Raman spectroscopy on its own is not sensitive enough to detect signals as small as changes in the levels of individual RNA molecules. To measure RNA levels, scientists typically use a technique called single-cell RNA sequencing, which can reveal the genes that are active within different types of cells in a tissue sample.

In this project, the MIT team sought to combine the advantages of single-cell RNA sequencing and Raman spectroscopy by training a computational model to translate Raman signals into RNA expression states.

“RNA sequencing gives you extremely detailed information, but it’s destructive. Raman is noninvasive, but it doesn’t tell you anything about RNA. So, the idea of this project was to use machine learning to combine the strength of both modalities, thereby allowing you to understand the dynamics of gene expression profiles at the single cell level over time,” Kobayashi-Kirschvink says.

To generate data to train their model, the researchers treated mouse fibroblast cells, a type of skin cell, with factors that reprogram the cells to become pluripotent stem cells. During this process, cells can also transition into several other cell types, including neural and epithelial cells.

Using Raman spectroscopy, the researchers imaged the cells at 36 time points over 18 days as they differentiated. After each image was taken, the researchers analyzed each cell using single molecule fluorescence in situ hybridization (smFISH), which can be used to visualize specific RNA molecules within a cell. In this case, they looked for RNA molecules encoding nine different genes whose expression patterns vary between cell types.

This smFISH data can then act as a link between Raman imaging data and single-cell RNA sequencing data. To make that link, the researchers first trained a deep-learning model to predict the expression of those nine genes based on the Raman images obtained from those cells.

Then, they used a computational program called Tangram, previously developed at the Broad Institute, to link the smFISH gene expression patterns with entire genome profiles that they had obtained by performing single-cell RNA sequencing on the sample cells.

The researchers then combined those two computational models into one that they call Raman2RNA, which can predict individual cells’ entire genomic profiles based on Raman images of the cells.

Tracking cell differentiation

The researchers tested their Raman2RNA algorithm by tracking mouse embryonic stem cells as they differentiated into different cell types. They took Raman images of the cells four times a day for three days, and used their computational model to predict the corresponding RNA expression profiles of each cell, which they confirmed by comparing it to RNA sequencing measurements.

Using this approach, the researchers were able to observe the transitions that occurred in individual cells as they differentiated from embryonic stem cells into more mature cell types. They also showed that they could track the genomic changes that occur as mouse fibroblasts are reprogrammed into induced pluripotent stem cells, over a two-week period.

“It’s a demonstration that optical imaging gives additional information that allows you to directly track the lineage of the cells and the evolution of their transcription,” So says.

The researchers now plan to use this technique to study other types of cell populations that change over time, such as aging cells and cancerous cells. They are now working with cells grown in a lab dish, but in the future, they hope this approach could be developed as a potential diagnostic for use in patients.

“One of the biggest advantages of Raman is that it’s a label-free method. It’s a long way off, but there is potential for the human translation, which could not be done using the existing invasive techniques for measuring genomic profiles,” says Jeon Woong Kang, an MIT research scientist who is also an author of the study.

The research was funded by the Japan Society for the Promotion of Science Postdoctoral Fellowship for Overseas Researchers, the Naito Foundation Overseas Postdoctoral Fellowship, the MathWorks Fellowship, the Helen Hay Whitney Foundation, the U.S. National Institutes of Health, the U.S. National Institute of Biomedical Imaging and Bioengineering, HubMap, the Howard Hughes Medical Institute, and the Klarman Cell Observatory.

[cytochrome-studyblr]

here's the shorthand i use in my notes as a biology major!

D or [delta] = change X = cross XD = exchange aX = across str = structure f'(x) = function j'(x) = junction [name of compound] = concentration of name of compound txn = transcription tln = translation [ionic] = ionic strength conc'n = concentration prok = prokaryotic or prokaryote euk = eukaryotic or eukaryote Ag = antigen Ab or [alpha] = antibody seq = sequence ss = single stranded ds = double stranded 1x = single 2x = double cross or 2 times fluo'scopy = fluorescent microscopy G+ve = Gram-positive G-ve = Gram-negative PoI = protein of interest GoI = gene of interest ish = in situ hybridization OH = alcohol (unspecified) NH2 = amine COOH = carboxyl or carboxylic acid C=O = carbonyl nt = nucleotide bp = base pair bp'ing = base pairing

ill add more as i think of them, this is just the shorthand i've developed over the course of several years ! use what works best for you always. this is just my system <3

[sarahmackattack]

you wouldn't happen to know any scools/labs/researchers in texas doing work with cephalopods, would you? i'm not yet very scientifically literate (just switched to a biology degree from art history), but octopus cognition and genomics interest me most so far. or like even any recommendations on how to get into those topics further since i'm still just a baby science major and still have a LOT to learn.

So before I start, I think it’s important for me to say the following:  You shouldn’t try to get a job with any of these scientists ONLY because you think cephalopods are cool.  Cephalopods are obviously extremely cool, and for most of us that’s what sparked our interest in the first place, but the main drive to do science is deeper than that. Marine biologists are trying to answer very specific questions about the physiology, camouflage, symbiosis, immune systems, behavior, etc. about these animals.  Being successful as a squid biologist requires three main interests.

1) Interest in cephalopods (which I’m pretty sure most followers of this blog have in spades)

2) Interest in the questions this scientist is asking(e.g.  How do squid immune cells recognize specific bacterial species?(Me)  How does the microbial community of the female squid’s accessory nidamental gland protect squid eggs? (Andrea)  How do cuttlefish perceive their world, and then decide what the best camouflage pattern is for the situation? (Roger Hanlon)  Do bacteria colonize animals differently in zero gravity? (Jamie Foster)

3) Interest in the techniques used to answer these questions.  (e.g. Confocal microscopy/Protein purification/ Western Blotting (Me), Fluorescence in situ hybridization (FISH)/Reverse transcriptase polymerase chain reaction (RT-PCR) /Culturing of environmental isolates/ bacterial growth assays (Andrea), Behavior studies/ Computational processing of camouflage pattern/ fieldwork (Roger)

Working with cephalopods is VERY COMPETITIVE, so you need to make sure you’re building your resume as early as possible.  Get research experience any way you can and educate yourself using peer reviewed literature when you’re at the academic level that you can start to understand it.

So now on to the list of scientists, in no particular order (all underlined names are links to more info about them)

Roger Hanlon (Woods Hole, Massachusetts, MBL) Literally wrote the book on cephalopod behavior. He works on camouflage and how cuttlefish perceive their environment, how they choose what camouflage pattern to use, and also works on the skin structures that contribute to camouflage. There’s an internship program through the MBL that his lab participates in but it’s very competitive.

Margaret McFall-Ngai (Hawaii, University of Hawaii) Margaret is the mother of the squid/vibrio symbiosis. A member of the national academy of sciences, Margaret has been extremely influential in the study of symbiosis. Working for her will be very competitive. She’s a great role model as a powerful woman in science.   Her lab, along with Ned Ruby’s lab, work on many aspects of the squid/vibrio symbiosis.  Many (if not all) of the squid/vibrio community have come through her or Ned’s labs.  Here’s a piece on her from nature blogs written by Ed Yong

Spencer Nyholm (Connecticut, UConn) Andrea and I work for Spencer, so you’ve probably seen our posts and have an idea of what we do, but I study how squid immune cells recognize specific bacterial species and Andrea studies how the microbial community of the female squid’s accessory nidamental gland can protect squid eggs.

Bethany Rader (Illinois, Southern Illinois University) Bethany is fantastic! She’s super friendly and excitable and just started her lab at SIU. She is one of our collaborators and previously did a post-doc in our lab. She’s working on the same thing I am, the role of the immune system in the squid/Vibrio symbiosis.

Bill Gilly (California, Stanford) Works on many aspects of Humboldt squid biology.

Josh Rosenthal (Puerto Rico, University of Puerto Rico) Works on RNA editing in squid and octopus.  I’ve heard he’s a really friendly guy but haven’t met him personally (yet).

Charlie Chubb (California, UC Irvine) Charlie is one of the genuinely nicest guys I have ever had the opportunity to work with.  He collaborates with Roger Hanlon, working on “ understanding the processes by which the visible world is constructed by the brain”.  He’s a brilliant scientist and a wonderful guy. His work is all computer based though so there are no physical squid in his lab.

Aran Mooney (Woods Hole, Massachusetts, Woods Hole Oceanographic Institution) Aran works on many different animals, but squid and cuttlefish are among them.  His synopsis on his website is as follows “Our research is in the sensory biology of animals, primarily marine organisms.  Specifically I am interested in how these animals detect the world around them, what they detect (i.e., what’s important to the organism), and how these animals then relate to their environment (e.g., predator detection, prey localization, habitat identification, and conspecific communication).”

Cheryl Whistler (New Hampshire, University of New Hampshire) Squid/Vibrio symbiosis.  I believe also how microbes have evolved to better colonize animals in beneficial symbiosis.

Jamie Foster (Florida, University of Florida) Working on host/microbe interactions in the squid/vibrio system.  Along with other things, she’s studying the effect of gravity on microbial colonization.   She also works on stromatolites.

Jean Boal (Pennsylvania, Millersville University)  Since Jean is at  Millersville she may not take grad students (I know when I was an undergrad she was not accepting grad students).  She works on cephalopod behavior.

Sheila Castellanoz-Martinez (Mexico) Immune system of cephalopods, specifically octopus.  She’s currently a Post-doc, but may have a lab soon, I really have no idea, I just read a lot of her papers J

Shelley Adamo (Canada, Dalhousie Univeristy) Currently working on insect innate immunity/behaviour but has worked on cuttlefish in the past and may work on cuttlefish in the future.

Maria Castillo (New Mexico, New Mexico State University) Role of the immune system in the squid/vibrio symbiosis

Michele Nishiguchi (New Mexico, New Mexico State University) Evolution and marine symbiosis in the squid/vibrio system

For more information, Tonmo is a great resource for all things cephalopod. They have information about everything from having a cephalopod as a pet to working with cephalopods. Here’s the board on education and employment.

[marketerefforts]

In Situ Hybridization Market Research Report 2023 - Industry Size, Share, Demands, Regional Analysis & Estimations Till 2028

The In Situ Hybridization��Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. The In Situ Hybridization industry growth avenues are deeply supported by exhaustive research by the top analysts of the industry. The report starts with the executive summary, followed by a value chain and marketing channels study. The report then estimates the CAGR and market revenue of the Global and regional segments.

Base Year: 2021

Estimated Year: 2022

Forecast Till: 2023 to 2028

The report classifies the market into different segments based on type and product. These segments are studied in detail, incorporating the market estimates and forecasts at regional and country levels. The segment analysis is helpful in understanding the growth areas and potential opportunities of the market.

Get | Download FREE Sample Report of Global In Situ Hybridization Market @ https://www.decisiondatabases.com/contact/download-sample-18103

A special section is dedicated to the analysis of the impact of the COVID-19 pandemic on the growth of the In Situ Hybridization market.  The impact is closely studied in terms of production, import, export, and supply.

The report covers the complete competitive landscape of the Worldwide In Situ Hybridization market with company profiles of key players such as:

Abbott Laboratories

Advanced Cell Diagnostics, Inc.

Agilent Technologies, Inc. 

Biogenex Laboratories, Inc.

Danaher Corporation

F.Hoffmann-La Roche Ltd.

Merck KGaA

Perkin Elmer, Inc.

Thermofisher Scientific, Inc.

Want to add more Company Profiles to the Report? Write your Customized Requirements to us @ https://www.decisiondatabases.com/contact/get-custom-research-18103

In Situ Hybridization Market Analysis by Technique:

Fluorescence In Situ Hybridization (FISH)

DNA-FISH

RNA-FISH

Chromogenic In Situ Hybridization (CISH)

In Situ Hybridization Market Analysis by Application:

Cancer Diagnosis

Immunology

Neuroscience

Cytology

Infectious Diseases

In Situ Hybridization Market Analysis by End-User:

Molecular Diagnostic Laboratories

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROS)

Academic & Research Institutions

In Situ Hybridization Market Analysis by Geography:

North America (USA, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Australia, South-East Asia, Rest of Asia-Pacific)

Latin America (Brazil, Argentina, Peru, Chile, Rest of Latin America)

The Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East and Africa)

Key questions answered in the report:

 What is the expected growth of the In Situ Hybridization market between 2023 to 2028?

Which application and type segment holds the maximum share in the Global In Situ Hybridization market?

Which regional In Situ Hybridization market shows the highest growth CAGR between 2023 to 2028?

What are the opportunities and challenges currently faced by the In Situ Hybridization market?

Who are the leading market players and what are their Strengths, Weakness, Opportunities, and Threats (SWOT)?

What business strategies are the competitors considering to stay in the In Situ Hybridization market?

Purchase the Complete Global In Situ Hybridization Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-18103

About Us:

DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 90 28 057900 Web: https://www.decisiondatabases.com/

[healthcaredbmrnews]

Molecular Diagnostics Market Overview, Growth Analysis, Share, Opportunities, Sales, Trends, Supply, Forecast To 2028

Molecular Diagnostics Market research report assists business in every sphere of trade to take superior decisions, to tackle the toughest business questions and diminish the risk of failure. What is more, emerging product trends, major drivers, challenges and opportunities in the market are recognized and analysed factually while generating this report. Market drivers and market restraints mentioned in this Molecular Diagnostics report help businesses gain an idea about the production strategy. Market shares of these key players in the major areas of the globe such as Europe, North America, Asia Pacific, South America, Middle East and Africa are also studied.

The molecular diagnostics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2021 to 2028 and is expected to reach USD     46,505.12 million by 2028. The demand for molecular diagnostics tools is increasing to diagnose COVID-19 patients, coupled with an increase in infectious disease and cancer prevalence as driver for the molecular diagnostics market growth.

Molecular diagnosis identifies or diagnoses diseases such as infectious diseases, genetic diseases, cardiovascular diseases, neurological diseases, and others by studying molecules such as DNA, RNA, protein in a tissue or a fluid. Different technologies such as PCR, mass spectrometry, next-generation sequencing, cytogenetics, in situ hybridization, molecular imaging, and others are used to diagnose different diseases. Molecular diagnostics use powerful tools such as gene expression profiling, DNA sequence analysis, and detection of biomarkers to determine the susceptibility of individuals to certain diseases or existing disease stage.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-molecular-diagnostics-market

The molecular diagnostics Market is segmented on the based on the products, technology, application and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of products, the global molecular diagnostics market is segmented into reagents & kits, instruments and services & softwares. Instruments are further segmented into fully automated instruments and semi-automated instruments. In 2021, the instruments segment is expected to dominate the molecular diagnostics market due to the rise in demand for advanced technology to diagnose diseases such as infectious diseases, cancer, and others.

On the basis of technology, the global molecular diagnostics market is segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The polymerase chain reaction (PCR)-based methods are further segmented into cold PCR, digital PCR, directlinear analysis, quantitative fluorescent PCR, real-time PCR and reverse transcriptase PCR. The molecular imaging segment is further subdivided into optical imaging and FDG-PET. In 2021, the polymerase chain reaction (PCR)-based methods segment is expected to dominate the molecular diagnostics market due to increased demand for PCR kits to diagnose COVID-19 and curb the pandemic.

On the basis of application, the global molecular diagnostics market is segmented into oncology, pharmacogenomics, microbiology, prenatal tests, tissue typing, blood screening, cardiovascular diseases, neurological diseases, infectious diseases and others. The oncology segment is further segmented into oncology, by cancer type and oncology, by technology. The oncology, by cancer type is further sub-divided into breast cancer, colorectal cancer, lung cancer, prostate cancer and others. The oncology, by technology is further sub-segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others.

The blood screening is further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others. The cardiovascular diseases are further segmented into mass spectrometry (MS), capillary electrophoresis, next generation sequencing (NGS), chips and microarray, polymerase chain reaction (PCR)-based methods, cytogenetics, in situ hybridization (ISH or FISH), molecular imaging and others.

On the basis of end user, the global molecular diagnostics market is segmented into hospital, clinical laboratories and academics. In 2021, the clinical laboratories segment is expected to dominate the molecular diagnostics market due to the rising number of patients with various illnesses and the growing need for diagnostics instruments.

Attractions of the Molecular Diagnostics Market Report: -

Latest market dynamics, development trends and growth opportunities are presented along with industry barriers, developmental threats and risk factors

The forecast Molecular Diagnostics Market data will help in the feasibility analysis, market size estimation and development

The report serves as a complete guide which micro monitors all vital Molecular Diagnostics Market

A concise market view will provide ease of understanding.

Molecular Diagnostics Competitive market view will help the players in making a right move

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-molecular-diagnostics-market

Table of Content:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Molecular Diagnostics Market Landscape

Part 04: Global Molecular Diagnostics Market Sizing

Part 05: Global Molecular Diagnostics Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

New Business Strategies, Challenges & Policies are mentioned, Request for Detailed TOC at https://www.databridgemarketresearch.com/toc/?dbmr=global-molecular-diagnostics-market

Key Questions Answered

What impact does COVID-19 have made on Global Molecular Diagnostics Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Molecular Diagnostics Market?

What are the key concerns of the five forces analysis of the Global Molecular Diagnostics Market?

What are different prospects and threats faced by the dealers in the Global Molecular Diagnostics Market?

What are the strengths and weaknesses of the key vendors?

Reasons to Purchase this Report:

Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects

Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

Market value USD Million and volume Units Million data for each segment and sub-segment

Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years

Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

The major companies which are dealing in the Molecular diagnostics are Abbott, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., BD, bioMérieux SA, Cepheid, Hologic, Inc., Life Technologies, Myriad Genetics, Inc., QIAGEN, Agilent Technologies, Inc., Quidel Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., IMMUCOR, Luminex Corporation, Meridian Bioscience, Hoffmann-La Roche Ltd, and GenMark Diagnostics, Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Trending Related Reports:

 Fitness App Market   

 Healthcare Interoperability Solutions Market         

 Health Tourism Market        

 Hospital Asset Management Market           

 HPV Testing & Pap test Market        

 Hysteroscopy Instruments Market   

 Interoperable Healthcare Solutions Market

 Laboratory Information Management Systems Market      

 Lithotripsy Devices Market   

 Long Term Care Software Market   

[drwaseemabbas]

Breast cancer treatment Delhi/India – Latest advancement Patient education and resources

 Patient information and resources

Latest advances in Breast cancer treatment

Node preservation reduces lymphedema cases-Can be done by Sentinal lymph node biopsy.

Genomic testing minimizes chemotherapy exposure-In detail described below.

Better identification of hereditary cancer syndromes.

An oral option for targeted therapy.

New drug combination makes estrogen-blocking agents more effective.

The next generation of monoclonal antibodies.

Immunotherapy in Triple negative Breast cancer.

Breast cancer is a curable disease in majority of patients.

Before describing about treatment of breast cancer we need to not only look at the stage of breast cancer but also at different prognostic and predictive biomarkers.

Apart from the stage, these biomarkers tell us about the probability of relapse

So, we divide breast cancer according to stage and according to the hormone receptor status and genomics. (By looking at genes we can also say that what kind of genes are driving cancer and how aggressive these genes are).

Classification of Breast cancer

A, As per Stage- Stage I, Stage II, Stage III, Stage IV.

B, As per Biomarkers-

Estrogen Receptor (ER)

Progesterone Receptor (PR)

Her2 Neu

C, Genomic test for Breast recurrence score-That measures the expression of cancer related genes in patients tumor.

Oncotype DX Breast recurrence score

Mammaprint

PAM 50

EndoPredict

Breast cancer can be divided   into subtypes   that respond differently to various types of treatment.

Subtypes according to Hormone receptor status

A, Hormone receptor positive – Estrogen receptor positive (ER-Positive), Progesterone receptor positive (PR-Positive) and Her2 Neu receptor negative are good biology tumors where chances of recurrence are less because they are good biology tumors. These breast cancers are 98% curable if diagnosed at early stage.

Can we avoid chemotherapy for such patients suffering from breast cancer?

Does that mean treating breast cancer without chemotherapy-Yes but not for all breast cancer patients

Yes, more breast cancer patients can avoid chemotherapy. With the help of genomic recurrence scores in breast cancer we can tell now who will benefit from chemotherapy. Not only in early-stage breast cancer, we can avoid chemotherapy in node positive breast cancer as well. From last 3 years 30% of our patients did not not receive chemotherapy after surgery for breast cancer. Now we can have better informed discussion with patients explaining why they are unlikely to benefit from chemotherapy in early-stage breast cancer.

This allows women suffering from Breast cancer to get through their cancer treatment faster and back to their lives sooner.

Cost remains a concern for such tests but in coming times it would go down so everyone can afford these tests.

In young breast cancer patients with advanced stage who are high risk for relapse ovarian suppression 

 B, Her2Neu positive Breast cancer – These are more aggressive that hormone receptor positive breast cancers. Such types of breast cancers are driven by Her2 Neu gene.

How are breast tumors tested for HER2?

By simple method called immunohistochemistry-IHC

If the IHC result is 0 or 1+, the cancer is considered HER2-negative. These cancers do not respond to treatment with drugs that target HER2.

If the IHC result is 3+, the cancer is HER2-positive. These cancers are usually treated with drugs that target HER2.

If the IHC result is 2+, the HER2 status of the tumor is not clear and is called “equivocal.” This means that the HER2 status needs to be tested with FISH to clarify the result.

If IHC report is 2-equivocal, it should be confirmed with FISH- Fluorescent in situ hybridization.

How to treat Her2 Neu positive breast cancer?

Chemotherapy cannot be avoided for such type of breast cancer unless tumor is less that 1cm. These are aggressive types of breast cancer and need targeted therapy along with chemotherapy.

Now different types of targeted therapies are available for such type of breast cancer and prognosis has improved with  advent of targeted therapies like Trastuzumab, Pertuzumab, Trstuzumab Emtasine (TDM-1), Lapatinib, Fam-Trastuzumab, Tucatinib, Enhertu (chemical name: fam-trastuzumab-deruxtecan etc.

C, TNBC-Triple negative Breast cancer- Tumor which is ER Negative, PR Negative and Her2Neu negative are called triple negative breast cancer. Triple negative Breast cancer is an aggressive cancer and has more like spread at the time of diagnosis and is more likely to come back after treatment.

In early stage 5 year survival rate is 90%, for breast cancer patients who are locally advanced (Stage II, Stage III) 5 year survival is 60% and for stage IV triple negative breast cancer patient 5 year survival is 10%.

These cancers are usually associated with BRCA 1 and BRCA 2 genes and other hereditary syndromes as well. So such breast cancer patients are diagnosed at early age. Some body diagnosed with Triple negative breast cancer should be screened for Hereditary syndromes after proper genetic counselling.

Treatment has not changed much as no targeted therapy is available for treatment of TNBC breast cancer patients. Immunotherapy is a new tool which is showing promise.

Immunotherapy for Triple negative Breast Cancer-Immunotherapy has changed the way we look at triple negative breast cancer. Different drugs called immune checkpoint inhibitors are available and are in early phase trials, have shown promising results

Immunotherapy for breast cancer can be combined with chemotherapy especially for locally advanced breast cancer. In neo adjuvant settings   it has shown good results in disease control for the first time in history. Research is going on and different clinical trials are addressing this issue.

Sofa we have seen more complete pathological responses with this approach.

C, TNBC-Triple negative breast cancer;-  Tumor which is ER-Negative,PR-Negative and Her2Neu-Negative.  -Aggressive type of breast cancer with high relapse rates .Now different drugs are available to cure this type of cancer. Immunotherapy is now a major tool to fight breast cancer.

Treatment of metastatic Breast cancer

Stage 4 breast cancer means that it is not curable, but that does not mean that breast cancer patients do not survive longer.

With newer drugs, better diagnostic techniques and better imaging modalities majority patients with stage 4 breast cancer survive beyond 5 years .

Again before starting treatment, we need to look at Estrogen receptor, Progesterone receptor and Her2Neu receptor status.

For ER, PR positive cancer patients and HerNeu negative   there is no need for chemotherapy, these patients can forgo chemotherapy and can be treated with hormonal therapy (Tamoxifen, Letrazole, Anastrazole, Exemestene) and other newer drugs called CDK4,6 Inhibitors (Palbociclib, Abemaciclib, Everolimus, Fulvestrant  etc) .

For Her2 Neu metastatic breast cancer patient newer drugs have shown promise in increasing survival.

For TNBC -Triple negative breast cancer survival remains poor and immunotherapy has shown promising results and more research is needed in this field.

Want to read to more about Breast cancer

1, Early detection of Breast cancer

2, Breast cancer screening

3, Sub types of Breast cancer

4, Treatment of high-risk breast cancer patients

5, Surgery for Breast cancer

Read More

[fostermarketarch]

Genetic Testing Market Prominent Growth And Vendor Landscape By 2025

The global genetic testing market was valued at US$ xx million in 2019. This market is estimated to be valued at US$ xx million in the year 2020, and it is expected to reach US$ xx million by the year 2025, with an estimated CAGR of xx% during the forecast period (2020−2025). Genetic testing is the study of gene present in tissues and cells. This study is further applied in the field of biology and medicine to know more about genetic disorders including down syndrome, sickle cell anemia, cancer, cystic fibrosis, and others.

The study discusses the use of gene tests for the development of targeted cancer treatment, personalized medicine, and other genetic diseases. Moreover, it highlights a wide range of techniques such as biochemical testing, cytogenetic testing/chromosome analysis, molecular testing, and DNA sequencing, which includes comparative genomic hybridization, karyotyping, fluorescence in situ hybridization, and others that are used for the screening of cancers and genetic abnormalities.

Key Insights:

Latest Updates

Analyst Views

Future Outlook of the Market

Get Free PDF Brochure of this Report @ https://www.fostermarketresearch.com/product/industry/biotechnology/global-genetic-testing-market/sample/

Competitive Landscape:

Major players in the global genetic testing market include: Bio-Rad Laboratories, Inc. (RainDance Technologies, Inc.), Abbott Laboratories, Myriad Genetics, Inc. (Myriad RBM, Inc.), Danaher Corporation (Cepheid), F. Hoffmann-La Roche Ltd., Eurofins Scientific, Illumina, Inc., Qiagen N.V., Novartis International AG, 23andMe, and Thermo Fisher Scientific, Inc. The other players in the genetic testing industry include Empire Genomics, LLC, Agilent Technologies, Inc., Irvine Scientific, PerkinElmer, Inc., and Sysmex Corporation, among others.

Market Taxonomy:

By Type

Predictive and Presymptomatic Testing

Carrier Testing

Prenatal & Newborn Testing

Diagnostic Testing

Nutrigenomic Testing

Pharmacogenomic Testing

Others

By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

By Application

Alzheimer’s Disease

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne Muscular Dystrophy

Huntington’s Disease

Thalassemia

Others

By Region

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Talk to Analyst @ https://www.fostermarketresearch.com/product/industry/biotechnology/global-genetic-testing-market/Talk-to-Analyst/

Market Dynamics:

The global genetic testing market is anticipated to register considerable growth in the forecast period due to increasing incidence of cancer & genetic disorders as well as rise in acceptance & awareness of personalized medicines. Additionally, advancements in genetic testing techniques and growing application of genetic testing in oncology are anticipated to propel the market growth during the review period. Diagnosis at the right time saves lives and reduces the number of deaths. According to The Institute for Health Metrics and Evaluation (IHME), about 8.9 million cancer deaths were documented in 2016, triggered by inheriting genetic mutation.

FAQ's:

Note: This report provides an in-depth analysis of the global genetic testing market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2025), considering 2019, as the base year.

What are the trends adopted by key players in the global genetic testing market?

What key factors are expected to increase the demand for genetic testing market during the forecast period 2020-2025?

What are the major challenges inhibiting the growth of the global genetic testing market?

What is the total market value (US$ Mn) generated in the global genetic testing market by type in 2019, and what are the forecasts by 2025?

Which technology is expected to dominate the global genetic testing market in the coming years?

Which application contribute highest CAGR (%) in the genetic testing market?

What was the total revenue generated by the global genetic testing market across different regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa) in 2019, along with CAGR (%) for the period (2020-2025)?

Who are the key players contributing to the growth of the global genetic testing market, and what are the new strategies adopted by them to retain a market share in the industry?

What is the competitive strength of the key players in the global genetic testing market?

What are the major outcomes derived from Porter’s five forces?

What are the new products which are going to be approved or launched in the upcoming years, which may have a huge impact on the market?

What insights are derived through the analysis of key players on the following parameters: company overview, financial performance, product portfolio, geographical presence, key highlights, and strategies?

Buy Now This Business Strategic Report to Improve Your Profits @ https://www.fostermarketresearch.com/product/buy/biotechnology/271/

About Foster Market Research:

Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.

Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.

Contact Us:

1701 Royal Lane, #1306, Dallas Tx-75229 Phone: +1 469 4981929 Email: support@fostermarketresearch.com

[marketresearchstrategy]

Nucleic Acid Labeling Industry Supply Chain Analysis, Growth Opportunities, Top Companies, Revenue Growth and Business Development Report by 2026

Increasing healthcare expenditure, rise in disease diagnosis, increase in R&D spending, increase in genomics research, rising demand for personalized medicine, rise in enzymology research and advancements in tools for synthetic genome design are key factors contributing to high CAGR of Nucleic Acid Labeling during forecast period.

the global Nucleic Acid Labeling market valued at USD 1.56 billion in 2018 and is expected to reach USD 3.08 billion by the year 2026, at a CAGR of 8.6%. A wide variety of molecular and cellular biology procedures are dependent on a labeled or tagged nucleic acid. These behavior and functioning can be specifically studied via the attached label. Nucleic acids can be easily labelled with several tags that allows their detection and purification. These tags can be used to recover or identify other interacting molecules.  The integrity of the nucleic acid is preserved in this non-destructive reaction, which makes it useful for applications where it is necessary to use the intact sample.

Owing to the growing demand for nucleic acid labeling, the manufacturers are adapting strategic initiatives such as innovative launch systems to increase their product portfolio. For example, with the launch of PHOTOPROBE labeling systems, the total length of the original nucleic acid sample, instead of copies, is directly marked. Additionally, Nucleic Acid Labeling can also be used for applications involving protein interactions, such as gel change or drip analysis, it is generally advantageous to generate labeled probes at the end to avoid steric interference of the interaction. The nucleic acid transfer can provide valuable information on gene integrity and copy number, as well as a means of analyzing mRNA size and expression gene, nucleic acid labeling helps to characterize cells and tissues developed in vitro and often produce important clinical information when used in patient samples. Moreover, the availability of different labels and a wide range of detection systems improve the sensitivity and flexibility required for in situ hybridization, thus, eventually driving the market growth for nucleic acid labeling.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2252

The report provides extensive coverage of the supply chain, key players of the industry, consumer base, company profiles, production and consumption rate, primary applications, and other relevant data. It provides an in-depth assessment of the key companies operating in the market along with their company profiles, business overview, production and manufacturing capacity, product portfolio, financial standing, global position, and business expansion plans. It also studies recent mergers and acquisitions, joint ventures, product launches, partnerships, collaborations, and agreements among other. The report also provides insights into new entrants and their strategic alliances to gain a robust footing in the market.

Key Manufacturers in the Global Nucleic Acid Labeling  Market:

Promega Corporation, Thermo Fisher Scientific, Inc., General Electric Company, New England Biolabs, PerkinElmer, Inc., F. Hoffmann La-Roche AG, Vector Laboratories, Merck KGaA, Enzo Biochem, and Agilent Technologies.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2252

The report also provides an extensive regional segmentation to offer the readers key insights into the spread of the market over key geographical regions. It covers production and consumption patterns, import/export, supply and demand, consumer demand and behavior, key trends, and presence of key players in each region. The report also offer a country-wise analysis to impart a better understanding of the revenue growth of the market in each region.

North America (U.S., Canada,     Mexico)

Europe (U.K., Italy, Germany,     France, Rest of Europe)

Asia Pacific (India, Japan, China,     South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina,     Rest of Latin America)

Middle East & Africa (Saudi     Arabia, U.A.E., South Africa, Rest of MEA)

Product Type (Revenue, USD Million; 2016–2026)

Reagents & Kits

Services

Technique Type (Revenue, USD Million; 2016–2026)

PCR

Nick Translation

Random Primer

In Vitro Transcription

Reverse Transcription

End Labeling

Label Type (Revenue, USD Million; 2016–2026)

Biotin-based

Fluorescent

Radioactive

End Use (Revenue, USD Million; 2016–2026)

Hospital

Clinic

Others

To know more about the report @ https://www.reportsanddata.com/report-detail/nucleic-acid-labeling-market

Key Questions Addressed in the Report:

What is     the market size the global Nucleic Acid Labeling  market is expected to reach over the     forecast period? What is the expected CAGR?

What     are the key segments of the market?

What     are the key products and applications of the Nucleic Acid Labeling  market?

What     factors are expected to drive and restrain market growth over the forecast     period?

What     are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2252

Thank you for reading our report. The report can be customized based on regional segmentation and competitive landscape. Kindly get in touch with us to know more and our team will ensure the report is well suited to meet your requirements.

Browse more related reports:

Cardiac Safety Services Market @ https://www.medgadget.com/2020/04/cardiac-safety-services-market-to-reach-usd-895-7-million-by-2026.html

Bio Decontamination Market @ https://www.medgadget.com/2020/04/bio-decontamination-market-to-reach-usd-195-7-million-by-2026.html

Non-Invasive Fat Reduction Market @ https://www.medgadget.com/2020/04/non-invasive-fat-reduction-market-to-reach-usd-2-83-billion-by-2026.html

Liquid Embolic Market @ https://www.medgadget.com/2020/03/liquid-embolic-market-to-reach-usd-3-27-billion-by-2027.html

Therapeutic Obstructive Sleep Apnea Devices Market @ https://www.medgadget.com/2020/03/therapeutic-obstructive-sleep-apnea-devices-market-to-reach-usd-6-22-billion-by-2026.html

Surgical Navigation Systems Market @ https://www.medgadget.com/2020/03/surgical-navigation-systems-market-to-reach-usd-1-21-billion-by-2026.html

[zanypaperprince]

Best multiple myeloma treatment in India

Multiple myeloma is cancer of the plasma cells (a type of white blood cells) of the bone marrow. Plasma cells are protein-making cells that generally produce the different kinds of antibodies for our immune system. In multiple myeloma, the plasma cells become malicious and cancerous. These myeloma cells stop making different forms of protein in response to the immune system's needs and instead start to produce a single abnormal type of protein sometimes termed a monoclonal or M protein. Multiple myeloma plasma cell populations accumulate in the bone marrow, and these collections of cells called plasmacytomas can erode the hard outer shell or cortex of the bone that normally surrounds the marrow. These weakened bones show thinning of the bone, as seen in nonmalignant osteoporosis or what appear to be punched out or lytic bone lesions. People often refer to multiple myeloma simply as myeloma (also termed Kahler's disease after the physician who first described this cancer). The disease usually occurs in people past middle age.

In India, there are large number of options available for Best multiple myeloma treatment in India.

However, rarely it can occur in a child. One type of myeloma-related plasma cell neoplasm is called a monoclonal gammopathy of undetermined significance (MGUS). In MGUS, medical professionals only find low levels of M protein and people have no symptoms; MGUS infrequently develops into multiple myeloma.

Plasma cell neoplasm is another name for multiple myeloma. Causes of multiple myeloma What triggers plasma cells into malicious multiple myeloma is unknown. The cancerous myeloma plasma cells proliferate and crowd out normal plasma cells and can corrode areas of bones. The proteins produced in large amounts can cause many of the symptoms of the disease by making the blood more viscous and depositing the proteins in organs that can interfere with the functions of the kidneys, nerves, and immune system.

Causes of multiple myeloma are not known exactly. But patients more likely to get affected • older than 65 years • people of African-American origin • overweight or obese people • family member with it

Stages of multiple myeloma

There are four stages of multiple myeloma. While many health care professionals use different staging, these are various stages cited by many clinicians:

• Smoldering: multiple myeloma with no symptoms • Stage I: early disease with little anemia, relatively small amount of M protein and no • bone damage • Stage II: more anemia and M protein as well as bone damage • Stage III: still more M protein, anemia, as well as signs of kidney damage Because staging criteria differ according to different groups, some clinicians simply define the individual's multiple myeloma without assigning a stage and simply estimate a prognosis for their patient.

Symptoms of multiple myeloma

Patients with myeloma may be asymptomatic with an unexplained increase in protein in the blood. With more advanced disease, some myeloma patients may have weakness due to anemia caused by inadequate production of red blood cells, with bone pain due to the bone damage, and as the abnormal M protein can accumulate and damage the kidneys resulting in patient’s unexplained kidney damage and decreased kidney function. Multiple myeloma cancer cells may be in or outside the bone marrow.

The following symptoms and signs of multiple myeloma -

• Anemia • Bleeding • Nerve damage • Bone tenderness or pain, including back pain • Enlarged tongue • Skin lesions (rash) • Infections Weakness, fatigue or tiredness • Kidney failure and/or other end-organ damage• Spinal cord compression • • Loss of appetite and weight loss • Leg swelling • Hypocalcaemia • Diagnosis of multiple myeloma • First sign of multiple myeloma is found when a routine blood test shows an abnormal amount of protein in the bloodstream or an unusual stickiness of red blood cells causing them to stack up almost like coins, an unusual formation for red blood cells. The health care professional will do a history and physical exam, looking for signs and symptoms of multiple myeloma. If multiple myeloma is suspected, several studies help confirm the diagnosis.

They include a bone marrow aspiration and biopsy most commonly from the large bones of the pelvis. Cells obtained from the marrow are studied by a pathologist to determine if there is one (plasmacytoma) or more (multiple myeloma) abnormal types or numbers of cells • Medical professionals also study a sample of the bone marrow aspirate for more detailed • Characteristics such as the presence or absence of abnormal numbers or types of chromosomes (DNA) by what is called cytogenetic testing.

Bone marrow biopsy can assess the concentrations of cells in the marrow and the presence of abnormal invasive growth of cellular elements. • Blood testing and urine testing by several methods can determine levels and types of National Comprehensive Cancer Network (NCCN) recommended that health care professionals use a serum free light chain assay and fluorescence in situ hybridization (FISH) test to further • Monoclonal protein produced and if there is kidney damage.

Identify multiple myeloma in patients

X-ray studies to identify skeletal lesions and MRI for spinal cord lesions in multiple myeloma.

Medical treatment for multiple myeloma

The therapy is decided based upon the patient's condition and the cancer management team, made with the patient's input. The choices for treatment(s) often include combinations of drugs, some of which medical professionals give as pills and others by intravenous injection.

These include drugs that affect or modulate the immune system, steroids, and some oral or injectable chemotherapy drugs. These are usually used in combinations. There may be a role for high-dose chemotherapy followed by the administration of bone marrow called a stem cell transplant. Numerous factors come into play in determining whether to do such a transplant. Other medical treatments may include steroids, bisphosphonate therapy, blood or platelet transfusions, plasmapheresis, and other combination therapy depending on the individual patient's disease stage.

Radiation therapy may treat painful areas of bone damage. Surgeons can surgically repair broken bones in many cases.

There are many drugs used to treat multiple myeloma. Medical professionals often use the following drugs in combination with dexamethasone,

• Bortezomib Velcade -- protease inhibitor • Lenalidomide (Revlimid) -- immune cell modulation • Melphalan (Alkeran) -- alkylating agent that is toxic to myeloma cells • Carfilzomib (Kyprolis) -- protease inhibitor that is FDA approved usually for patients • who have failed a previous treatment • Daratumumab (Darzalex) -- monoclonal antibody that may damage or kill multiple • Myeloma cells (and others) that have CD38 protein on their surface • Elotuzumab (Empliciti) -- a compound that activates the body's natural killer cells to • Destroy multiple myeloma cells, usually in combination with Revlimid and Decadron • Ninlaro (Ixazomib) -- This proteasome inhibitor, in combination with Revlimid and • Dexamethasone, improves the survival rates of some patients with multiple myeloma.

Hospitals offer best multiple myeloma treatment in India, the charges for autologous stem cell transplant ranges between USD 15000 to USD 21000 depending on the status of the disease and individual's response to the treatment provided at the hospitals.

Related Articles -

Best multiple myeloma treatment hospitals in India

Best Sickle cell disease treatment in India

Best Bone marrow transplant hospitals in India

Are you looking for Lymphoma treatment in India

About GHN Healthcare -

GHN Healthcare Services is a leading Medical treatment Assistance Company based in New Delhi (National Capital region), India. The Organization actively engaged in providing Medical assistance to foreign Patients who choose to travel to India for quality medical care at a reasonable cost. GHN Healthcare Services is associated with 25+ Top-Notch Hospitals and has a network of 500+ Super Specialists to offer world-class medical care at a reasonable cost.

For any enquiries related to Multiple myeloma treatment in India. Click here...

[evoldir]

Postdoc:ULausanne.EvolutionaryGenomicsNeurogenetics

A postdoc position is available within the lab of Roman Arguello at University of Lausanne's (UNIL) Department of Ecology and Evolution. We are a newly formed lab interested in understanding the genetic and neural bases of sensory evolution. We take a very interdisciplinary approach that bridges computational/comparative genomics with neurogenetics. Our model organisms are diverse Drosophila species from around the globe, and we are particularly interested in the evolution of neural circuits and in the evolutionary processes related to the rapid changes underlying olfaction and temperature preference. The specific focus for this position will be on olfactory evolution. The projects will relate repeated gains/losses in olfactory receptors to the evolution of their protein sequences, to their neural circuits, and to behavior. This work will test hypotheses about how the olfactory system evolves, and to what extent these changes are repeatable. Due to the cross-disciplinary nature of the research, there is a range of opportunities for contributing to the projects depending on particular interests and strengths (i.e. comparative/population genomics, neurobiology, generation of transgenic tools for new species). Qualification include a PhD in genetics, evolutionary biology, neurobiology, or a related field, the ability to be self-motivated and to work independently as well as within a small group, good communication skills, comfortable with public presentations, and the ability to clearly document work. Additionally, expertise with several of the following tasks is required, and an interest/willingness to learn some of the others: - molecular evolution and/or population genomic analyses - statistics and next-generation sequence analyses (programming/scripting in one or more languages such as Python, Perl, R, etc.) - molecular biology (CRISPR/Cas9 vector designs) - electrophysiology - histochemistry/microscopy (dissecting, tissue preparations, antibody staining, fluorescent in situ hybridization, confocal imaging) - fly genetics and maintenance - fly embryo injections for generating transgenic lines and screening This is a 100% position for an initial duration of one year, renewable up to 2 or 3 years depending on the start date and funding available. The position is dedicated primarily to research, however some contribution to teaching is expected, including the possibility of assisting with the supervision of master students. The Department of Ecology and Evolution is a lively, fun, productive, and highly diverse group. While UNIL is a French-speaking university, the working language of the Department and the Lab is English. For more information about the Department of Ecology and Evolution please see its page here: http://bit.ly/2lGIr6Y Lausanne is a scenic medium-sized city situated on the edge of Lake Geneva. Life here is good. Its central location within Europe makes traveling by train and plane convenient. And for outdoor enthusiasts, Lausanne sits at the base of Alps and Jura which offer year-round escape and fun. For more information about the Lab, or for further questions, please visit: arguellolab.org or email Roman at: jacob.arguello@unil.ch Formal applications need to be done through HR, and must include a cover letter detailing your research interests and background, a CV, and the contact info for references (2-3). Applications should both be uploaded through the University of Lausanne platform (link given below), and sent as a single pdf to jacob.arguello@unil.ch. Application Link: https://bit.ly/2Ge0DA5 University equality policy: The University of Lausanne promotes an equitable representation of men and women among its staff and encourages applications from women and minority groups. via Gmail